[Successful rituximab monotherapy in a patient with mucosa-associated lymphoid tissue lymphoma of the rectum with trisomy 3, 18].
A 62-year-old man was referred to our hospital with enlargement of mucosa-associated lymphoid tissue (MALT) lymphoma of the rectum after the eradication of Helicobacter pylori. The patient was given a diagnosis of stage I MALT. Endoscopic observation revealed an enlarged rectal tumor with 3, 18 double trisomy. Rituximab monotherapy was given and complete remission was achieved. Rituximab monotherapy can be useful for MALT lymphoma of the rectum.
Kagawa
Miwako
M
Department of Gastroenterology and Oncology, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan.
Okamura
Seisuke
S
Okamoto
Koichi
K
Kitamura
Shinji
S
Kimura
Tetsuo
T
Niki
Miyako
M
Kaji
Masako
M
Okahisa
Toshiya
T
Yano
Mitsuyasu
M
Kagawa
Seiko
S
Kudo
Eiji
E
Sano
Toshiaki
T
Imoto
Yoshitaka
Y
Wada
Satoshi
S
Takayama
Tetsuji
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002900:Chromosomes, Human, 1-3; D002902:Chromosomes, Human, 16-18; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D000069283:Rituximab; D014314:Trisomy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab